Cerebrospinal fluid ATP as a potential biomarker in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes (MELAS)

Takamasa Nukui, Atsushi Matsui, Hideki Niimi, Mamoru Yamamoto, Noriyuki Matsuda, Jin Lan Piao, Kyo Noguchi, Isao Kitajima, Yuji Nakatsuji*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is caused by defective oxidative phosphorylation in the cerebral parenchyma, cerebral blood vessels, and leptomeningeal tissue. Although increased blood and cerebrospinal fluid (CSF) lactate level has been used as a diagnostic biomarker in patients with MELAS, no biomarkers reflecting disease activity exist. Since we have developed a highly sensitive ATP assay system using luciferase luminous reaction, we examined CSF ATP in patients with MELAS and found that it negatively correlates with disease activity and that it reflects the efficacy of the treatment. CSF ATP might be a novel disease monitoring marker for MELAS.

Original languageEnglish
Pages (from-to)145-148
Number of pages4
JournalMitochondrion
Volume50
DOIs
StatePublished - 2020/01

Keywords

  • ATP
  • Biomarker
  • Cerebrospinal fluid
  • MELAS

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Cerebrospinal fluid ATP as a potential biomarker in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes (MELAS)'. Together they form a unique fingerprint.

Cite this